Transpek Industry Ltd

- No specific mention of any current or planned fundraising through debt or equity during the call. - Company remains a very low debt entity with a strong balance sheet. - Capital expenditure (CAPEX) for new facilities will only be considered once new products reach critical mass in 1.5-2 years. - There is a cautious approach to deploying funds, ensuring clear demand visibility before investing in new capacities. - No updates provided on raising funds via equity; however, the company is in the process of NSE listing, expected by April end, which might indirectly support future fundraising. - No explicit discussion of raising debt to fund growth or expansions at this stage.

- Transpek is cautious with capital expenditure (capex), deploying funds only when there is clear demand visibility to ensure effective deployment. - Currently, with a revenue run rate of ~Rs. 700 crores and about 65% capacity utilization, they have roughly 30-35% spare capacity that can be used for new products. - New products (4-5-7 products) are expected to ramp up over the next 1.5 to 2 years; only after building critical volume will new capacity expansion be considered. - Initial production of new non-acid chloride products may require converting existing facilities; future capacity addition may happen within the factory, adjacent plots, or through inorganic growth/job work. - Company has explored inorganic growth opportunities but has not finalized any due to high price or misalignment with company values. - No immediate significant capex planned; capital investment decisions will be driven by product ramp-up and market demand. - NSE listing process is underway, expected to complete by April 2025.

- Expect about 10% growth in revenues for FY26, similar to current range. - Specialty new products (3-4 in number) targeted to generate Rs. 150-200 crores annually by FY27 with ~20% EBITDA margins. - Ramp-up of 4-5-7 new products is awaited before considering significant new capacity addition (~1.5-2 years timeline). - Current capacity utilization is around 65%, with 30-35% spare capacity available for new products. - New non-acid chloride products expected to start commercial supply next year, with gradual volume build-up. - Sustained demand expected under key contracts (e.g., DuPont) with steady volumes and no major dips. - Careful capital deployment and capacity expansion only after clear demand visibility. - Incremental volumes expected from upgraded Kevlar EXO product (from Jan 2026) leading to modest volume and margin improvements.

- Transpek expects about 10% revenue growth for the next fiscal year (FY26), with no significant changes currently visible. - New products, particularly 3-4 upcoming acid chloride and non-acid chloride products, are expected to generate Rs. 150-200 crores annually within 2 years, contributing higher value addition and around 20% EBITDA margins. - Current capacity utilization is about 65%, with 30-35% spare capacity that can be used for ramping up new products without major new capital expenditure immediately. - Significant capital investment or capacity expansion will only be considered after proper ramp-up and critical mass of new products in 1.5-2 years. - The long-term DuPont contract is steady; renewal discussions expected in 1-1.5 years but current demand is stable, supporting consistent earnings. - EBITDA margins currently stand at ~17.9%, slightly lower YoY by 70 bps, with potential improvement as higher-margin products ramp up. - Overall, growth is anticipated through product diversification and steady customer demand with cautious CAPEX.

- Transpek Industry Limited currently maintains steady demand from key customers, including a 10-year contract with DuPont, with about 1 to 1.5 years remaining before renewal discussions begin. - The company expects to sustain existing supply volumes under current contracts without significant changes in demand or supply in the near term. - Discussions on contract renewals (e.g., with DuPont) have not yet commenced, with no new information available at present. - The company is introducing 4-5-7 new specialty products expected to ramp up over the next 1.5 to 2 years, which will contribute to future order growth and new capacity considerations. - Some new Indian customers have been added recently, signaling incremental order inflow. - NSE listing procedures are nearing completion, expected by April-end, potentially aiding future business development and order inflows.